Skip to main content
Top
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

The maximum standardized uptake value of 18 F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancer

Authors: Jian Zhang, Zhen Jia, Joseph Ragaz, Ying-Jian Zhang, Min Zhou, Yong-Ping Zhang, Gang Li, Bi-Yun Wang, Zhong-Hua Wang, Xi-Chun Hu

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

Whether PET scan maximum standard uptake value (SUVmax) could differentiate luminal A from luminal B and help predict the survival of metastatic breast cancer (MBC) patients with luminal subtype is still unknown and need to be investigated.

Methods

305 MBC patients with luminal subtypes were screened with PET/CT. Eligible patients were prospectively followed up.

Results

In total, 134 patients were eligible for this study. SUVmax was significantly related to the number of metastatic sites and presence of visceral metastasis on univariate analysis. SUVmax could not effectively differentiate patients with luminal A from luminal B subtype. Although luminal subtype at diagnosis could predict the relapse-free interval, it could not predict progression-free survival (PFS) or overall survival (OS) after developing relapse. In contrast, SUVmax was predictive of both PFS and OS and this effect was maintained in multivariate COX regression model.

Conclusions

SUVmax of MBC did not correlate with molecular subtypes of primary tumor. While molecular subtype may be a valuable prognostic factor at primary diagnosis of breast cancer, the SUVmax, rather than molecular subtype, does have a potential to predict independently in multivariate analysis for the PFS and OS in patients with metastatic disease of luminal subtype.
Appendix
Available only for authorised users
Literature
1.
go back to reference Youlden DR, Cramb SM, Dunn NA, Muller JM, Pyke CM, Baade PD: The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality. Cancer Epidemiol. 2012, 36 (3): 237-248. 10.1016/j.canep.2012.02.007.CrossRefPubMed Youlden DR, Cramb SM, Dunn NA, Muller JM, Pyke CM, Baade PD: The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality. Cancer Epidemiol. 2012, 36 (3): 237-248. 10.1016/j.canep.2012.02.007.CrossRefPubMed
2.
go back to reference Brewster AM, Hortobagyi GN, Broglio KR, Kau SW, Santa-Maria CA, Arun B, Buzdar AU, Booser DJ, Valero V, Bondy M, et al: Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst. 2008, 100 (16): 1179-1183. 10.1093/jnci/djn233.CrossRefPubMed Brewster AM, Hortobagyi GN, Broglio KR, Kau SW, Santa-Maria CA, Arun B, Buzdar AU, Booser DJ, Valero V, Bondy M, et al: Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst. 2008, 100 (16): 1179-1183. 10.1093/jnci/djn233.CrossRefPubMed
3.
go back to reference Mariani G: New developments in the treatment of metastatic breast cancer: from chemotherapy to biological therapy. Ann Oncol. 2005, 16 (Suppl 2): i191-i194. Mariani G: New developments in the treatment of metastatic breast cancer: from chemotherapy to biological therapy. Ann Oncol. 2005, 16 (Suppl 2): i191-i194.
4.
go back to reference Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001, 98 (19): 10869-10874. 10.1073/pnas.191367098.CrossRefPubMedPubMedCentral Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001, 98 (19): 10869-10874. 10.1073/pnas.191367098.CrossRefPubMedPubMedCentral
5.
go back to reference Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, et al: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006, 295 (21): 2492-2502. 10.1001/jama.295.21.2492.CrossRefPubMed Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, et al: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006, 295 (21): 2492-2502. 10.1001/jama.295.21.2492.CrossRefPubMed
6.
go back to reference Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, et al: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009, 101 (10): 736-750. 10.1093/jnci/djp082.CrossRefPubMedPubMedCentral Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, et al: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009, 101 (10): 736-750. 10.1093/jnci/djp082.CrossRefPubMedPubMedCentral
7.
go back to reference Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, et al: The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006, 7: 96-10.1186/1471-2164-7-96.CrossRefPubMedPubMedCentral Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, et al: The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006, 7: 96-10.1186/1471-2164-7-96.CrossRefPubMedPubMedCentral
8.
go back to reference Perou CM, Jeffrey SS, van de Rijn M, Rees CA, Eisen MB, Ross DT, Pergamenschikov A, Williams CF, Zhu SX, Lee JC, et al: Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA. 1999, 96 (16): 9212-9217. 10.1073/pnas.96.16.9212.CrossRefPubMedPubMedCentral Perou CM, Jeffrey SS, van de Rijn M, Rees CA, Eisen MB, Ross DT, Pergamenschikov A, Williams CF, Zhu SX, Lee JC, et al: Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA. 1999, 96 (16): 9212-9217. 10.1073/pnas.96.16.9212.CrossRefPubMedPubMedCentral
9.
go back to reference Alavi A, Lakhani P, Mavi A, Kung JW, Zhuang H: PET: a revolution in medical imaging. Radiol Clin North Am. 2004, 42 (6): 983-1001. 10.1016/j.rcl.2004.08.012.CrossRefPubMed Alavi A, Lakhani P, Mavi A, Kung JW, Zhuang H: PET: a revolution in medical imaging. Radiol Clin North Am. 2004, 42 (6): 983-1001. 10.1016/j.rcl.2004.08.012.CrossRefPubMed
10.
go back to reference Allal AS, Slosman DO, Kebdani T, Allaoua M, Lehmann W, Dulguerov P: Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18 F]fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys. 2004, 59 (5): 1295-1300. 10.1016/j.ijrobp.2003.12.039.CrossRefPubMed Allal AS, Slosman DO, Kebdani T, Allaoua M, Lehmann W, Dulguerov P: Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18 F]fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys. 2004, 59 (5): 1295-1300. 10.1016/j.ijrobp.2003.12.039.CrossRefPubMed
11.
go back to reference Downey RJ, Akhurst T, Gonen M, Vincent A, Bains MS, Larson S, Rusch V: Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol. 2004, 22 (16): 3255-3260. 10.1200/JCO.2004.11.109.CrossRefPubMed Downey RJ, Akhurst T, Gonen M, Vincent A, Bains MS, Larson S, Rusch V: Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol. 2004, 22 (16): 3255-3260. 10.1200/JCO.2004.11.109.CrossRefPubMed
12.
go back to reference Sasaki R, Komaki R, Macapinlac H, Erasmus J, Allen P, Forster K, Putnam JB, Herbst RS, Moran CA, Podoloff DA, et al: [18 F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol. 2005, 23 (6): 1136-1143. 10.1200/JCO.2005.06.129.CrossRefPubMed Sasaki R, Komaki R, Macapinlac H, Erasmus J, Allen P, Forster K, Putnam JB, Herbst RS, Moran CA, Podoloff DA, et al: [18 F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol. 2005, 23 (6): 1136-1143. 10.1200/JCO.2005.06.129.CrossRefPubMed
13.
go back to reference Kitajima K, Kita M, Suzuki K, Senda M, Nakamoto Y, Sugimura K: Prognostic significance of SUVmax (maximum standardized uptake value) measured by [(18)F]FDG PET/CT in endometrial cancer. Eur J Nucl Med Mol Imaging. 2012, 39 (5): 840-845. 10.1007/s00259-011-2057-9.CrossRefPubMed Kitajima K, Kita M, Suzuki K, Senda M, Nakamoto Y, Sugimura K: Prognostic significance of SUVmax (maximum standardized uptake value) measured by [(18)F]FDG PET/CT in endometrial cancer. Eur J Nucl Med Mol Imaging. 2012, 39 (5): 840-845. 10.1007/s00259-011-2057-9.CrossRefPubMed
14.
go back to reference Lee YY, Choi CH, Kim CJ, Kang H, Kim TJ, Lee JW, Lee JH, Bae DS, Kim BG: The prognostic significance of the SUVmax (maximum standardized uptake value for F-18 fluorodeoxyglucose) of the cervical tumor in PET imaging for early cervical cancer: preliminary results. Gynecol Oncol. 2009, 115 (1): 65-68. 10.1016/j.ygyno.2009.06.022.CrossRefPubMed Lee YY, Choi CH, Kim CJ, Kang H, Kim TJ, Lee JW, Lee JH, Bae DS, Kim BG: The prognostic significance of the SUVmax (maximum standardized uptake value for F-18 fluorodeoxyglucose) of the cervical tumor in PET imaging for early cervical cancer: preliminary results. Gynecol Oncol. 2009, 115 (1): 65-68. 10.1016/j.ygyno.2009.06.022.CrossRefPubMed
15.
go back to reference Namura K, Minamimoto R, Yao M, Makiyama K, Murakami T, Sano F, Hayashi N, Tateishi U, Ishigaki H, Kishida T, et al: Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18 F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report. BMC Cancer. 2010, 10: 667-10.1186/1471-2407-10-667.CrossRefPubMedPubMedCentral Namura K, Minamimoto R, Yao M, Makiyama K, Murakami T, Sano F, Hayashi N, Tateishi U, Ishigaki H, Kishida T, et al: Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18 F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report. BMC Cancer. 2010, 10: 667-10.1186/1471-2407-10-667.CrossRefPubMedPubMedCentral
16.
go back to reference Pan L, Gu P, Huang G, Xue H, Wu S: Prognostic significance of SUV on PET/CT in patients with esophageal cancer: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2009, 21 (9): 1008-1015. 10.1097/MEG.0b013e328323d6fa.CrossRefPubMed Pan L, Gu P, Huang G, Xue H, Wu S: Prognostic significance of SUV on PET/CT in patients with esophageal cancer: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2009, 21 (9): 1008-1015. 10.1097/MEG.0b013e328323d6fa.CrossRefPubMed
17.
go back to reference Shimoda W, Hayashi M, Murakami K, Oyama T, Sunagawa M: The relationship between FDG uptake in PET scans and biological behavior in breast cancer. Breast Cancer. 2007, 14 (3): 260-268. 10.2325/jbcs.14.260.CrossRefPubMed Shimoda W, Hayashi M, Murakami K, Oyama T, Sunagawa M: The relationship between FDG uptake in PET scans and biological behavior in breast cancer. Breast Cancer. 2007, 14 (3): 260-268. 10.2325/jbcs.14.260.CrossRefPubMed
18.
go back to reference Geyer FC, Rodrigues DN, Weigelt B, Reis-Filho JS: Molecular classification of estrogen receptor-positive/luminal breast cancers. Adv Anat Pathol. 2012, 19 (1): 39-53. 10.1097/PAP.0b013e31823fafa0.CrossRefPubMed Geyer FC, Rodrigues DN, Weigelt B, Reis-Filho JS: Molecular classification of estrogen receptor-positive/luminal breast cancers. Adv Anat Pathol. 2012, 19 (1): 39-53. 10.1097/PAP.0b013e31823fafa0.CrossRefPubMed
19.
go back to reference Macfarlane R, Seal M, Speers C, Woods R, Masoudi H, Aparicio S, Chia SK: Molecular alterations between the primary breast cancer and the subsequent locoregional/metastatic tumor. Oncologist. 2012, 17 (2): 172-178. 10.1634/theoncologist.2011-0127.CrossRefPubMedPubMedCentral Macfarlane R, Seal M, Speers C, Woods R, Masoudi H, Aparicio S, Chia SK: Molecular alterations between the primary breast cancer and the subsequent locoregional/metastatic tumor. Oncologist. 2012, 17 (2): 172-178. 10.1634/theoncologist.2011-0127.CrossRefPubMedPubMedCentral
20.
go back to reference Simmons C, Miller N, Geddie W, Gianfelice D, Oldfield M, Dranitsaris G, Clemons MJ: Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?. Ann Oncol. 2009, 20 (9): 1499-1504. 10.1093/annonc/mdp028.CrossRefPubMedPubMedCentral Simmons C, Miller N, Geddie W, Gianfelice D, Oldfield M, Dranitsaris G, Clemons MJ: Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?. Ann Oncol. 2009, 20 (9): 1499-1504. 10.1093/annonc/mdp028.CrossRefPubMedPubMedCentral
21.
go back to reference Liedtke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF, Albarracin C, Meric-Bernstam F, Woodward W, Theriault RL, et al: Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol. 2009, 20 (12): 1953-1958. 10.1093/annonc/mdp263.CrossRefPubMedPubMedCentral Liedtke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF, Albarracin C, Meric-Bernstam F, Woodward W, Theriault RL, et al: Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol. 2009, 20 (12): 1953-1958. 10.1093/annonc/mdp263.CrossRefPubMedPubMedCentral
22.
go back to reference Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Dowsett M: Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol. 2005, 23 (11): 2469-2476. 10.1200/JCO.2005.01.172.CrossRefPubMed Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Dowsett M: Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol. 2005, 23 (11): 2469-2476. 10.1200/JCO.2005.01.172.CrossRefPubMed
23.
go back to reference Amir E, Miller N, Geddie W, Freedman O, Kassam F, Simmons C, Oldfield M, Dranitsaris G, Tomlinson G, Laupacis A, et al: Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol. 2012, 30 (6): 587-592. 10.1200/JCO.2010.33.5232.CrossRefPubMed Amir E, Miller N, Geddie W, Freedman O, Kassam F, Simmons C, Oldfield M, Dranitsaris G, Tomlinson G, Laupacis A, et al: Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol. 2012, 30 (6): 587-592. 10.1200/JCO.2010.33.5232.CrossRefPubMed
24.
go back to reference Amir E, Clemons M, Purdie CA, Miller N, Quinlan P, Geddie W, Coleman RE, Freedman OC, Jordan LB, Thompson AM: Tissue confirmation of disease recurrence in breast cancer patients: Pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treat Rev. 2011, 38 (6): 708-714.CrossRefPubMed Amir E, Clemons M, Purdie CA, Miller N, Quinlan P, Geddie W, Coleman RE, Freedman OC, Jordan LB, Thompson AM: Tissue confirmation of disease recurrence in breast cancer patients: Pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treat Rev. 2011, 38 (6): 708-714.CrossRefPubMed
25.
go back to reference Munoz M, Fernandez-Acenero MJ, Martin S, Schneider J: Prognostic significance of molecular classification of breast invasive ductal carcinoma. Arch Gynecol Obstet. 2009, 280 (1): 43-48. 10.1007/s00404-008-0867-1.CrossRefPubMed Munoz M, Fernandez-Acenero MJ, Martin S, Schneider J: Prognostic significance of molecular classification of breast invasive ductal carcinoma. Arch Gynecol Obstet. 2009, 280 (1): 43-48. 10.1007/s00404-008-0867-1.CrossRefPubMed
26.
go back to reference Martoni AA, Zamagni C, Quercia S, Rosati M, Cacciari N, Bernardi A, Musto A, Fanti S, Santini D, Taffurelli M: Early (18)F-2-fluoro-2-deoxy-d-glucose positron emission tomography may identify a subset of patients with estrogen receptor-positive breast cancer who will not respond optimally to preoperative chemotherapy. Cancer. 2010, 116 (4): 805-813. 10.1002/cncr.24820.CrossRefPubMed Martoni AA, Zamagni C, Quercia S, Rosati M, Cacciari N, Bernardi A, Musto A, Fanti S, Santini D, Taffurelli M: Early (18)F-2-fluoro-2-deoxy-d-glucose positron emission tomography may identify a subset of patients with estrogen receptor-positive breast cancer who will not respond optimally to preoperative chemotherapy. Cancer. 2010, 116 (4): 805-813. 10.1002/cncr.24820.CrossRefPubMed
27.
go back to reference Ueda S, Tsuda H, Saeki T, Omata J, Osaki A, Shigekawa T, Ishida J, Tamura K, Abe Y, Moriya T, et al: Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study. Breast Cancer. 2011, 18 (4): 299-308. 10.1007/s12282-010-0212-y.CrossRefPubMed Ueda S, Tsuda H, Saeki T, Omata J, Osaki A, Shigekawa T, Ishida J, Tamura K, Abe Y, Moriya T, et al: Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study. Breast Cancer. 2011, 18 (4): 299-308. 10.1007/s12282-010-0212-y.CrossRefPubMed
28.
go back to reference Humbert O, Berriolo-Riedinger A, Riedinger JM, Coudert B, Arnould L, Cochet A, Loustalot C, Fumoleau P, Brunotte F: Changes in 18 F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes. Ann Oncol. 2012, 23 (10): 2572-2577. 10.1093/annonc/mds071.CrossRefPubMed Humbert O, Berriolo-Riedinger A, Riedinger JM, Coudert B, Arnould L, Cochet A, Loustalot C, Fumoleau P, Brunotte F: Changes in 18 F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes. Ann Oncol. 2012, 23 (10): 2572-2577. 10.1093/annonc/mds071.CrossRefPubMed
29.
go back to reference Kolesnikov-Gauthier H, Vanlemmens L, Baranzelli MC, Vennin P, Servent V, Fournier C, Carpentier P, Bonneterre J: Predictive value of neoadjuvant chemotherapy failure in breast cancer using FDG-PET after the first course. Breast Cancer Res Treat. 2012, 131 (2): 517-525. 10.1007/s10549-011-1832-4.CrossRefPubMed Kolesnikov-Gauthier H, Vanlemmens L, Baranzelli MC, Vennin P, Servent V, Fournier C, Carpentier P, Bonneterre J: Predictive value of neoadjuvant chemotherapy failure in breast cancer using FDG-PET after the first course. Breast Cancer Res Treat. 2012, 131 (2): 517-525. 10.1007/s10549-011-1832-4.CrossRefPubMed
30.
go back to reference Constantinidou A, Martin A, Sharma B, Johnston SR: Positron emission tomography/computed tomography in the management of recurrent/metastatic breast cancer: a large retrospective study from the Royal Marsden Hospital. Ann Oncol. 2011, 22 (2): 307-314. 10.1093/annonc/mdq343.CrossRefPubMed Constantinidou A, Martin A, Sharma B, Johnston SR: Positron emission tomography/computed tomography in the management of recurrent/metastatic breast cancer: a large retrospective study from the Royal Marsden Hospital. Ann Oncol. 2011, 22 (2): 307-314. 10.1093/annonc/mdq343.CrossRefPubMed
31.
go back to reference Couturier O, Jerusalem G, N’Guyen JM, Hustinx R: Sequential positron emission tomography using [18 F]fluorodeoxyglucose for monitoring response to chemotherapy in metastatic breast cancer. Clin Cancer Res. 2006, 12 (21): 6437-6443. 10.1158/1078-0432.CCR-06-0383.CrossRefPubMed Couturier O, Jerusalem G, N’Guyen JM, Hustinx R: Sequential positron emission tomography using [18 F]fluorodeoxyglucose for monitoring response to chemotherapy in metastatic breast cancer. Clin Cancer Res. 2006, 12 (21): 6437-6443. 10.1158/1078-0432.CCR-06-0383.CrossRefPubMed
32.
go back to reference Tateishi U, Gamez C, Dawood S, Yeung HW, Cristofanilli M, Macapinlac HA: Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. Radiology. 2008, 247 (1): 189-196. 10.1148/radiol.2471070567.CrossRefPubMed Tateishi U, Gamez C, Dawood S, Yeung HW, Cristofanilli M, Macapinlac HA: Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. Radiology. 2008, 247 (1): 189-196. 10.1148/radiol.2471070567.CrossRefPubMed
33.
go back to reference De Giorgi U, Mego M, Rohren EM, Liu P, Handy BC, Reuben JM, Macapinlac HA, Hortobagyi GN, Cristofanilli M, Ueno NT: 18 F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. J Nucl Med. 2010, 51 (8): 1213-1218. 10.2967/jnumed.110.076455.CrossRefPubMed De Giorgi U, Mego M, Rohren EM, Liu P, Handy BC, Reuben JM, Macapinlac HA, Hortobagyi GN, Cristofanilli M, Ueno NT: 18 F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. J Nucl Med. 2010, 51 (8): 1213-1218. 10.2967/jnumed.110.076455.CrossRefPubMed
34.
go back to reference Morris PG, Ulaner GA, Eaton A, Fazio M, Jhaveri K, Patil S, Evangelista L, Park JY, Serna-Tamayo C, Howard J, et al: Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer. Cancer. 2012, 118 (22): 5454-5462. 10.1002/cncr.27579.CrossRefPubMed Morris PG, Ulaner GA, Eaton A, Fazio M, Jhaveri K, Patil S, Evangelista L, Park JY, Serna-Tamayo C, Howard J, et al: Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer. Cancer. 2012, 118 (22): 5454-5462. 10.1002/cncr.27579.CrossRefPubMed
35.
go back to reference Boellaard R, Oyen WJ, Hoekstra CJ, Hoekstra OS, Visser EP, Willemsen AT, Arends B, Verzijlbergen FJ, Zijlstra J, Paans AM, et al: The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging. 2008, 35 (12): 2320-2333. 10.1007/s00259-008-0874-2.CrossRefPubMed Boellaard R, Oyen WJ, Hoekstra CJ, Hoekstra OS, Visser EP, Willemsen AT, Arends B, Verzijlbergen FJ, Zijlstra J, Paans AM, et al: The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging. 2008, 35 (12): 2320-2333. 10.1007/s00259-008-0874-2.CrossRefPubMed
36.
go back to reference Boellaard R: Mutatis mutandis: harmonize the standard!. J Nucl Med. 2012, 53 (1): 1-3. 10.2967/jnumed.111.094763.CrossRefPubMed Boellaard R: Mutatis mutandis: harmonize the standard!. J Nucl Med. 2012, 53 (1): 1-3. 10.2967/jnumed.111.094763.CrossRefPubMed
Metadata
Title
The maximum standardized uptake value of 18 F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancer
Authors
Jian Zhang
Zhen Jia
Joseph Ragaz
Ying-Jian Zhang
Min Zhou
Yong-Ping Zhang
Gang Li
Bi-Yun Wang
Zhong-Hua Wang
Xi-Chun Hu
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-42

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine